Id1 immortalizes hematopoietic progenitors in vitro and promotes a myeloproliferative disease in vivo

Oncogene

Volumn 27, Issue 42, 2008, Pages 5612-5623

  Suh, H C ^a,b   Leeanansaksiri, W ^a,b   Ji, M ^a,b   Klarmann, K D ^a,b   Renn, K ^a,b   Gooya, J ^a,b   Smith, D ^c   McNiece, I ^c   Lugthart, S ^d   Valk, P J M ^d   Delwel, R ^d   Keller, J R ^a,b  

^a SAIC FREDERICK INC   (United States)

^b NATIONAL CANCER INSTITUTE   (United States)

^c JOHNS HOPKINS UNIVERSITY   (United States)

^d ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

Id1; Leukemia; Myeloproliferative disease; Prevention; Therapeutic target

Indexed keywords

INHIBITOR OF DIFFERENTIATION 1;

ADULT; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER INHIBITION; CELL GROWTH; CELL IMMORTALIZATION; CELL PROLIFERATION; CONTROLLED STUDY; DEREGULATION; FEMALE; HEMATOPOIETIC STEM CELL; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; INHIBITOR OF DIFFERENTIATION PROTEIN GENE; LEUKEMIA CELL; MALE; MOUSE; MYELOID PROGENITOR CELL; MYELOPROLIFERATIVE DISORDER; NONHUMAN; ONCOGENE; PRIORITY JOURNAL; PROTEIN EXPRESSION;

ANIMALS; BONE MARROW CELLS; CELL DIFFERENTIATION; CELL LINE, TUMOR; CELL PROLIFERATION; CYCLIN-DEPENDENT KINASES; GRANULOCYTE COLONY-STIMULATING FACTOR; GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR; HEMATOPOIETIC STEM CELLS; HUMANS; INHIBITOR OF DIFFERENTIATION PROTEIN 1; MICE; MICE, INBRED C57BL; MYELOPROLIFERATIVE DISORDERS;

MUS;

EID: 52149106901     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/onc.2008.175     Document Type: Article

References (49)

1. Akashi K, He X, Chen J, Iwasaki H, Niu C, Steenhard B et al. (2003). Transcriptional accessibility for genes of multiple tissues and hematopoietic lineages is hierarchically controlled during early hematopoiesis. Blood 101: 383-389.
2. Akashi K, Reya T, Dalma-Weiszhausz D, Weissman IL. (2000a). Lymphoid precursors. Curr Opin Immunol 12: 144-150.
3. Akashi K, Traver D, Miyamoto T, Weissman IL. (2000b). A clonogenic common myeloid progenitor that gives rise to all myeloid lineages. Nature 404: 193-197.
4. Alani RM, Hasskarl J, Grace M, Hernandez MC, Israel MA, Munger K. (1999). Immortalization of primary human keratinocytes by the helix-loop-helix protein, Id-1. Proc Natl Acad Sci USA 96: 9637-9641.
5. Alani RM, Young AZ, Shifflett CB. (2001). Id1 regulation of cellular senescence through transcriptional repression of p16/Ink4a. Proc Natl Acad Sci USA 98: 7812-7816.
6. Bain G, Engel I, Robanus Maandag EC, Te Riele HP, Voland JR, Sharp LL et al. (1997). E2A deficiency leads to abnormalities in alphabeta T-cell development and to rapid development of T-cell lymphomas. Mol Cell Biol 17: 4782-4791.
7. Belletti B, Drakas R, Morrione A, Tu X, Prisco M, Yuan T et al. (2002). Regulation of Id1 protein expression in mouse embryo fibroblasts by the type 1 insulin-like growth factor receptor. Exp Cell Res 277: 107-118.
8. Buitenhuis M, Van Deutekom HW, Verhagen LP, Castor A, Jacobsen SE, Lammers JW et al. (2005). Differential regulation of granulopoiesis by the basic helix-loop-helix transcriptional inhibitors Id1 and Id2. Blood 105: 4272-4281.
9. Bullinger L, Valk PJ. (2005). Gene expression profiling in acute myeloid leukemia. J Clin Oncol 23: 6296-6305.
10. Castilla LH, Garrett L, Adya N, Orlic D, Dutra A, Anderson S et al. (1999). The fusion gene Cbfb-MYH11 blocks myeloid differentiation and predisposes mice to acute myelomonocytic leukaemia. Nat Genet 23: 144-146.
11. Cooper CL, Brady G, Bilia F, Iscove NN, Quesenberry PJ. (1997). Expression of the Id family helix-loop-helix regulators during growth and development in the hematopoietic system. Blood 89: 3155-3165.
12. Fong S, Debs RJ, Desprez PY. (2004). Id genes and proteins as promising targets in cancer therapy. Trends Mol Med 10: 387-392.
13. Grisolano JL, Wesselschmidt RL, Pelicci PG, Ley TJ. (1997). Altered myeloid development and acute leukemia in transgenic mice expressing PML-RAR alpha under control of cathepsin G regulatory sequences. Blood 89: 376-387.
14. He LZ, Tribioli C, Rivi R, Peruzzi D, Pelicci PG, Soares V et al. (1997). Acute leukemia with promyelocytic features in PML/RARalpha transgenic mice. Proc Natl Acad Sci USA 94: 5302-5307.
15. Higuchi M, O'Brien D, Kumaravelu P, Lenny N, Yeoh EJ, Downing JR. (2002). Expression of a conditional AML1-ETO oncogene bypasses embryonic lethality and establishes a murine model of human t(8;21) acute myeloid leukemia. Cancer Cell 1: 63-74.
16. Hollnagel A, Oehlmann V, Heymer J, Ruther U, Nordheim A. (1999). Id genes are direct targets of bone morphogenetic protein induction in embryonic stem cells. J Biol Chem 274: 19838-19845.
17. Hu M, Krause D, Greaves M, Sharkis S, Dexter M, Heyworth C et al. (1997). Multilineage gene expression precedes commitment in the hemopoietic system. Genes Dev 11: 774-785.
18. Ishiguro A, Spirin K, Shiohara M, Tobler A, Norton JD, Rigolet M et al. (1995). Expression of Id2 and Id3 mRNA in human lymphocytes. Leuk Res 19: 989-996.
19. Jen Y, Weintraub H, Benezra R. (1992). Overexpression of Id protein inhibits the muscle differentiation program: in vivo association of Id with E2A proteins. Genes Dev 6: 1466-1479.
20. Kang Y, Chen CR, Massague J. (2003). A self-enabling TGFbeta response coupled to stress signaling: Smad engages stress response factor ATF3 for Id1 repression in epithelial cells. Mol Cell 11: 915-926.
21. Kim D, Peng XC, Sun XH. (1999). Massive apoptosis of thymocytes in T-cell-deficient Id1 transgenic mice. Mol Cell Biol 19: 8240-8253.
22. Kogan SC, Ward JM, Anver MR, Berman JJ, Brayton C, Cardiff RD et al. (2002). Bethesda proposals for classification of nonlymphoid hematopoietic neoplasms in mice. Blood 100: 238-245.
23. Kondo M, Weissman IL, Akashi K. (1997). Identification of clonogenic common lymphoid progenitors in the mouse bone marrow. Cell 91: 661-672.
24. Koschmieder S, Rosenbauer F, Steidl U, Owens BM, Tenen DG. (2005). Role of transcription factors C/EBPalpha and PU.1 in normal hematopoiesis and leukemia. Int J Hematol 81: 368-377.
25. Kreider BL, Benezra R, Rovera G, Kadesch T. (1992). Inhibition of myeloid differentiation by the helix-loop-helix protein Id. Science 255: 1700-1702.
26. Kunisato A, Chiba S, Saito T, Kumano K, Nakagami-Yamaguchi E, Yamaguchi T et al. (2004). Stem cell leukemia protein directs hematopoietic stem cell fate. Blood 103: 3336-3341.
27. Lasorella A, Noseda M, Beyna M, Yokota Y, Iavarone A. (2000). Id2 is a retinoblastoma protein target and mediates signalling by Myc oncoproteins. Nature 407: 592-598.
28. Lasorella A, Uo T, Iavarone A. (2001). Id proteins at the cross-road of development and cancer. Oncogene 20: 8326-8333.
29. Leeanansaksiri W, Wang H, Gooya JM, Renn K, Abshari M, Tsai S et al. (2005). IL-3 induces inhibitor of DNA-binding protein-1 in hemopoietic progenitor cells and promotes myeloid cell development. J Immunol 174: 7014-7021.
30. Lyden D, Hattori K, Dias S, Costa C, Blaikie P, Butros L et al. (2001). Impaired recruitment of bone-marrow-derived endothelial and hematopoietic precursor cells blocks tumor angiogenesis and growth. Nat Med 7: 1194-1201.
31. Nilsson L, Eden P, Olsson E, Mansson R, Astrand-Grundstrom I, Strombeck B et al. (2007). The molecular signature of MDS stem cells supports a stem cell origin of 5q- myelodysplastic syndromes. Blood 110: 3005-3014.
32. Norton JD. (2000). ID helix-loop-helix proteins in cell growth, differentiation and tumorigenesis. J Cell Sci 113(Pt 22): 3897-3905.
33. Ohtani N, Zebedee Z, Huot TJ, Stinson JA, Sugimoto M, Ohashi Y et al. (2001). Opposing effects of Ets and Id proteins on p16INK4a expression during cellular senescence. Nature 409: 1067-1070.
34. O'Neil J, Shank J, Cusson N, Murre C, Kelliher M. (2004). TAL1/SCL induces leukemia by inhibiting the transcriptional activity of E47/HEB. Cancer Cell 5: 587-596.
35. Pagliuca A, Gallo P, De Luca P, Lania L. (2000). Class A helix-loop-helix proteins are positive regulators of several cyclin-dependent kinase inhibitors' promoter activity and negatively affect cell growth. Cancer Res 60: 1376-1382.
36. Perk J, Iavarone A, Benezra R. (2005). Id family of helix-loop-helix proteins in cancer. Nat Rev Cancer 5: 603-614.
37. Prabhu S, Ignatova A, Park ST, Sun XH. (1997). Regulation of the expression of cyclin-dependent kinase inhibitor p21 by E2A and Id proteins. Mol Cell Biol 17: 5888-5896.
38. Quesenberry PJ, Iscove NN, Cooper C, Brady G, Newburger PE, Stein GS et al. (1996). Expression of basic helix-loop-helix transcription factors in explant hematopoietic progenitors. J Cell Biochem 61: 478-488.
39. Rosenbauer F, Koschmieder S, Steidl U, Tenen DG. (2005). Effect of transcription-factor concentrations on leukemic stem cells. Blood 106: 1519-1524.
40. Rosmarin AG, Yang Z, Resendes KK. (2005). Transcriptional regulation in myelopoiesis: hematopoietic fate choice, myeloid differentiation, and leukemogenesis. Exp Hematol 33: 131-143.
41. Ruzinova MB, Benezra R. (2003). Id proteins in development, cell cycle and cancer. Trends Cell Biol 13: 410-418.
42. Sikder HA, Devlin MK, Dunlap S, Ryu B, Alani RM. (2003). Id proteins in cell growth and tumorigenesis. Cancer Cell 3: 525-530.
43. Suh HC, Gooya J, Renn K, Friedman AD, Johnson PF, Keller JR. (2006). C/EBPalpha determines hematopoietic cell fate in multipotential progenitor cells by inhibiting erythroid differentiation and inducing myeloid differentiation. Blood 107: 4308-4316.
44. Tenen DG. (2003). Disruption of differentiation in human cancer: AML shows the way. Nat Rev Cancer 3: 89-101.
45. Valk PJ, Verhaak RG, Beijen MA, Erpelinck CA, Barjesteh van Waalwijk van Doorn-Khosrovani S, Boer JM et al. (2004). Prognostically useful gene-expression profiles in acute myeloid leukemia. N Engl J Med 350: 1617-1628.
46. Wilson RB, Kiledjian M, Shen CP, Benezra R, Zwollo P, Dymecki SM et al. (1991). Repression of immunoglobulin enhancers by the helix-loop-helix protein Id: implications for B-lymphoid-cell development. Mol Cell Biol 11: 6185-6191.
47. Wong YC, Wang X, Ling MT. (2004). Id-1 expression and cell survival. Apoptosis 9: 279-289.
48. Yokota Y, Mori S. (2002). Role of Id family proteins in growth control. J Cell Physiol 190: 21-28.
49. Zhang J, Kalkum M, Yamamura S, Chait BT, Roeder RG. (2004). E protein silencing by the leukemogenic AML1-ETO fusion protein. Science 305: 1286-1289.